{"id":"at-527-single-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"headache"},{"rate":null,"effect":"nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"AT-527 specifically targets the RNA-dependent RNA polymerase of viruses, which is essential for the transcription and replication of viral RNA. By inhibiting this enzyme, AT-527 prevents the virus from producing new viral particles, thus reducing viral load and potentially alleviating disease symptoms.","oneSentence":"AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:55:49.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of SARS-CoV-2 infection"}]},"trialDetails":[{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT07272889","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":24},{"nctId":"NCT06911320","phase":"PHASE1","title":"Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-09","conditions":"Healthy Volunteer Study, Hepatic Impairment, Renal Impairment","enrollment":28},{"nctId":"NCT07007806","phase":"PHASE1","title":"Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-05-09","conditions":"Healthy Volunteer Study","enrollment":20},{"nctId":"NCT06921941","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-08","conditions":"Healthy Volunteer Study","enrollment":38},{"nctId":"NCT05724693","phase":"PHASE1","title":"Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-01-30","conditions":"Healthy Volunteer, Hepatic Impairment","enrollment":39},{"nctId":"NCT05618314","phase":"PHASE1","title":"Study of AT-527 in Subjects With Normal and Impaired Renal Function","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2022-10-17","conditions":"Healthy Volunteer, Renal Impairment","enrollment":36},{"nctId":"NCT05905484","phase":"PHASE1","title":"Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-04-25","conditions":"Healthy Volunteer Study","enrollment":35},{"nctId":"NCT05256732","phase":"PHASE1","title":"Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2022-02-22","conditions":"Healthy Volunteer Study","enrollment":136},{"nctId":"NCT04309734","phase":"PHASE1, PHASE2","title":"Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects","status":"WITHDRAWN","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2021-10","conditions":"Hepatitis C, Hepatitis C, Chronic, Chronic Hepatitis C","enrollment":""},{"nctId":"NCT05137626","phase":"PHASE1","title":"Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2021-11-03","conditions":"Healthy Volunteers Study","enrollment":29},{"nctId":"NCT05154123","phase":"PHASE1","title":"Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998)","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2021-11-16","conditions":"Healthy Volunteer Study","enrollment":29},{"nctId":"NCT05004415","phase":"PHASE1","title":"Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2021-07-28","conditions":"Healthy Volunteer Study","enrollment":6},{"nctId":"NCT03219957","phase":"PHASE1","title":"Study of AT-527 in Healthy and HCV-Infected Subjects","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2017-07-06","conditions":"Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic","enrollment":88}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bemnifosbuvir"],"phase":"phase_1","status":"active","brandName":"AT-527 single dose","genericName":"AT-527 single dose","companyName":"Atea Pharmaceuticals, Inc.","companyId":"atea-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AT-527 is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, thereby blocking viral replication. Used for Treatment of SARS-CoV-2 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}